Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Research

Pharmaceutical

Science

Biotechnology

SunRock Biopharma

More Like This

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family

Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago

Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research

PR Newswire associated0

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate

Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma

MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

PR Newswire associated0

Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates